Back |
home / stock / labp / labp message board
Subject | By | Source | When |
---|---|---|---|
$LABP 42s getting smashed | TrendTrade2016 | investorshub | 12/19/2022 7:28:26 PM |
$LABP getting jiggy...46c break sends it | TrendTrade2016 | investorshub | 12/19/2022 5:23:51 PM |
Another 30% today, betting news gonna drop, lotta volume | RAND | investorshub | 12/15/2022 9:30:09 PM |
https://twitter.com/Tickeron/status/1603080268578816000?t=jMipGEdykhcWp4uVA qt3Q | RAND | investorshub | 12/14/2022 6:42:13 PM |
ER being released Aug 11 after market close | Hungry_Ghost | investorshub | 08/09/2022 2:42:40 AM |
Thanks. | Hungry_Ghost | investorshub | 08/03/2022 1:36:55 PM |
Landos Biopharma Reports Positive Top-Line Results From NX-13 | subslover | investorshub | 08/03/2022 12:50:23 PM |
O/S. 40 million | Hungry_Ghost | investorshub | 07/15/2022 1:30:19 PM |
How about the float or As or OS. | Harbor6460 | investorshub | 07/15/2022 4:53:15 AM |
Great expansive pipeline, 70 million million in the | Hungry_Ghost | investorshub | 07/08/2022 4:48:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Landos Biopharma Inc. Company Name:
LABP Stock Symbol:
NASDAQ Market:
Landos Biopharma Inc. Website:
2024-05-26 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AbbVie Completes Acquisition of Landos Biopharma PR Newswire - Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill....
2024-05-06 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...